Medicaid Claims for Contraception Among Women With Medical Conditions After Release of the US Medical Eligibility Criteria for Contraceptive Use
ORIGINAL RESEARCH — Volume 16 — January 3, 2019
PEER REVIEWED
Figure 1.
Changes in percentage of women, by medical condition, with a Medicaid claim for family planning management from the 2-year period before (2008 and 2009) to the 2-year period after (2011 and 2012) the 2010 release of the US Medical Eligibility Criteria for Contraceptive Use (MEC) by the Centers for Disease Control and Prevention (1). Percentage is number of women with each medical condition and an FPM Medicaid claim relative to the total population for that condition.
MEC Medical Condition | Before (2008-2009), % | After (2011-2012), % |
---|---|---|
Bariatric surgery | 12.6 | 18.8 |
Breast cancer | 7.4 | 8.6 |
Diabetes | 16.9 | 17.8 |
Endometrial and ovarian cancer | 4.7 | 7.3 |
Epilepsy | 18.8 | 18.8 |
Malignant gestational trophoblastic disease | 27.1 | 17.9 |
Human immunodeficiency virus | 11.8 | 15.5 |
Hypertension | 17.2 | 18.3 |
Ischemic heart disease | 8.5 | 9.8 |
Liver cancer | 4.4 | 6.7 |
Lupus | 17.3 | 19.1 |
Solid organ transplant | 6.1 | 12.8 |
Peripartum cardiomyopathy | 46.6 | 44.8 |
Sickle cell disease | 23.8 | 24.4 |
Severe cirrhosis | 11.6 | 13.5 |
Stroke | 11.4 | 12.7 |
Thrombogenic heart disease | 24.3 | 23.6 |
Tuberculosis | 19.2 | 19.5 |
Valvular heart disease | 18.3 | 18.4 |
Figure 2.
Changes in percentage of women, by medical condition, with a Medicaid claim for a highest efficacy contraception method from the 2-year period before (2008 and 2009) to the 2-year period after (2011 and 2012) the 2010 release of the US Medical Eligibility Criteria for Contraceptive Use (MEC) by the Centers for Disease Control and Prevention (1). Highest efficacy methods are contraceptive implants, intrauterine devices, and sterilization. Percentage is number of women with each medical condition and an HEM Medicaid claim relative to the total population for that condition.
MEC Medical Condition | Before MEC (2008 and 2009), % | After MEC (2011 and 2012), % |
---|---|---|
Bariatric surgery | 2.2 | 6.2 |
Breast cancer | 1.9 | 3.1 |
Diabetes | 4.3 | 6.0 |
Endometrial and ovarian cancer | 0.9 | 2.3 |
Epilepsy | 3.8 | 5.1 |
Human immunodeficiency virus | 2.5 | 4.2 |
Hypertension | 4.3 | 5.8 |
Ischemic heart disease | 2.0 | 3.2 |
Lupus | 3.9 | 5.9 |
Peripartum cardiomyopathy | 19.8 | 25.6 |
Sickle cell disease | 3.6 | 5.3 |
Severe cirrhosis | 2.4 | 4.1 |
Stroke | 2.9 | 4.7 |
Thrombogenic heart disease | 8.6 | 10.2 |
Tuberculosis | 3.5 | 5.9 |
Valvular heart disease | 4.9 | 6.5 |
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.